货号:A159794
同义名:
Campathecin; CPT
Camptothecin (CPT) 是一种生物碱,作为 DNA 拓扑异构酶 I (Topo I) 抑制剂,IC50 为 679 nM。它对结直肠癌、乳腺癌、肺癌和卵巢癌表现出强效的抗肿瘤活性,并通过改变人类癌细胞中的微小 RNA (miRNA) 表达模式来调节缺氧诱导因子 1α (HIF-1α) 活性。
HazMat Fee + There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.
| Type | HazMat fee for 500 gram (Estimated) |
| Excepted Quantity | USD 0.00 |
| Limited Quantity | USD 15-60 |
| Inaccessible (Haz class 6.1), Domestic | USD 80+ |
| Inaccessible (Haz class 6.1), International | USD 150+ |
| Accessible (Haz class 3, 4, 5 or 8), Domestic | USD 100+ |
| Accessible (Haz class 3, 4, 5 or 8), International | USD 200+ |


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 产品名称 | Topo I ↓ ↑ | Topo II ↓ ↑ | Topo IV ↓ ↑ | Topoisomerase ↓ ↑ | 其他靶点 | 纯度 | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ellagic acid | ✔ | 98% | |||||||||||||||||
| β-Lapachone | ✔ | 99%+ | |||||||||||||||||
| (s)-10-hydroxycamptothecin | ✔ | 98+% | |||||||||||||||||
| Camptothecin |
++
Topo I, IC50: 0.68 μM |
98% | |||||||||||||||||
| Betulinic acid |
++
Eukaryotic topoisomerase I, IC50: 5 μM |
98% | |||||||||||||||||
| Topotecan |
++++
Topo I (MCF-7 Luc cells), IC50: 13 nM Topo I (DU-145 Luc cells), IC50: 2 nM |
98% | |||||||||||||||||
| Irinotecan HCl Trihydrate | ✔ | 98% | |||||||||||||||||
| SN-38 | ✔ | 98% | |||||||||||||||||
| Levofloxacin hydrate | ✔ | 98% | |||||||||||||||||
| Dexrazoxane | ✔ | 99%+ | |||||||||||||||||
| Ofloxacin | ✔ | 98+% | |||||||||||||||||
| Enoxacin | ✔ | 99%+ | |||||||||||||||||
| Flumequine |
+
Topo II, IC50: 15 μM |
98% | |||||||||||||||||
| Levofloxacin | ✔ | 97% | |||||||||||||||||
| Etoposide | ✔ | 98% | |||||||||||||||||
| Pefloxacin mesylate dihydrate | ✔ | 99.5% | |||||||||||||||||
| Marbofloxacin | ✔ | 98+% | |||||||||||||||||
| Voreloxin HCl | ✔ | 98% | |||||||||||||||||
| Mitoxantrone 2HCl | ✔ | PKC | 98% | ||||||||||||||||
| Nalidixic acid | ✔ | 98% | |||||||||||||||||
| Doxorubicin | ✔ | 97% | |||||||||||||||||
| Novobiocin sodium | ✔ | 95% | |||||||||||||||||
| Amonafide | ✔ | 99%+ | |||||||||||||||||
| Pirarubicin | ✔ | 98%+ | |||||||||||||||||
| Idarubicin HCl |
+++
Topo II (MCF-7 cells), IC50: 3.3 ng/mL |
99%+ | |||||||||||||||||
| Genistein | ✔ | EGFR | 98% | ||||||||||||||||
| Teniposide | ✔ | 98% | |||||||||||||||||
| Moxifloxacin | ✔ | 98% | |||||||||||||||||
| Ciprofloxacin | ✔ | 98% | |||||||||||||||||
| Clinafloxacin | ✔ | 99% | |||||||||||||||||
| Gatifloxacin | ✔ | 98% | |||||||||||||||||
| Daunorubicin HCl |
+++
DNA synthesis, Ki: 20 nM |
98% | |||||||||||||||||
| Epirubicin HCl | ✔ | 99%+ | |||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 靶点 |
|
| 描述 | Camptothecin (CPT), an alkaloid, acts as an inhibitor for DNA topoisomerase I (Topo I) with an IC50 value of 679 nM[1]. Demonstrating significant antitumor effects on colorectal, breast, lung, and ovarian cancers, CPT also affects the activity of hypoxia-inducible factor-1α (HIF-1α) by altering the patterns of microRNAs (miRNA) expression in human cancer cells[2].[3]. |
| 体内研究 | Administering Camptothecin (2 mg/kg every other day) to mice presenting extensive pulmonary metastases resulted in a significant reduction of these metastases when combined with the kinase inhibitor of nuclear factor-kappaB-1 (KINK-1)[5]. |
| 体外研究 | MCF7 (Luminal subtype) and HCC1419 (HER2 subtype) cells, characterized by elevated TOP1 enzyme activity, are particularly susceptible to Camptothecin treatment (ranging from 0.1 μM to 5 μM over 72 hours), showing IC50 values of 0.089 μM and 0.067 μM, respectively[4]. A dosage of Camptothecin at 0.5 μM for 6 and 24 hours notably decreases the expression of VEGF activated by desferrioxamine. Furthermore, Camptothecin administration (0.5 μM; 8 to 24 hours) effectively inhibits the accumulation of HIF-1α induced by desferrioxamine[2]. |
| Concentration | Treated Time | Description | References | |
| CCRF-CEM SLFN11-del and parental cells | 100 nM | 4 hours | Short treatments with CPT (4 hours) induced potent inhibition of DNA replication regardless of SLFN11 | Mol Cell. 2018 Feb 1;69(3):371-384.e6. |
| K562 | 100 nM | 24 hours | Evaluate cytotoxicity of CPT on K562 cells | Proc Natl Acad Sci U S A. 2021 Feb 9;118(6):e2015654118. |
| HEK293 | 100 nM | 24 hours | Evaluate cytotoxicity of CPT on HEK293 cells | Proc Natl Acad Sci U S A. 2021 Feb 9;118(6):e2015654118. |
| DMS114 | 100 nM | 24 hours | Evaluate cytotoxicity of CPT on DMS114 cells | Proc Natl Acad Sci U S A. 2021 Feb 9;118(6):e2015654118. |
| CCRF-CEM | 100 nM | 24 hours | Evaluate cytotoxicity of CPT on CCRF-CEM cells | Proc Natl Acad Sci U S A. 2021 Feb 9;118(6):e2015654118. |
| DU145 SLFN11 KO | 100 nM | 24 hours | Evaluate cytotoxicity of CPT on SLFN11 KO cells | Proc Natl Acad Sci U S A. 2021 Feb 9;118(6):e2015654118. |
| Mouse embryonic fibroblasts (MEFs) | 1 μM | 1 hour | Used to study CPT-induced DNA double-strand breaks (DSBs) repair. Results showed that Exo1−/− and Exo1DA/DA MEFs had significantly reduced co-localization of activated pRPA-S4/S8 and γH2AX, indicating the critical role of EXO1 nuclease activity in DSB repair. | Nucleic Acids Res. 2022 Aug 12;50(14):8093-8106 |
| HEK293 cells | 50 nM | 1 h | To analyze the direct effects of PrimPolS538A at the replication fork, a DNA fiber assay was used to assess ongoing replication after UV damage. Despite increased UV-C sensitivity, both PrimPolS538A and PrimPolS538E had minimal effect on fork stalling, suggesting that the genotoxic effects of PrimPolS538A may be initiated outside of S phase replication. | Sci Adv. 2021 Dec 3;7(49):eabh1004. |
| U2OS cells | 1 µM | 1 h | To assess the impact of USP21 knockdown on BRCA2 protein levels, results showed that USP21 knockdown led to a significant reduction in BRCA2 protein levels | Nat Commun. 2017 Jul 26;8(1):137. |
| MEFs | 30 nM | 24 h | To evaluate the effect of Camptothecin-induced single-strand breaks converted into double-strand breaks during DNA replication and observe RAD51 foci formation. Results showed that 30 nM Camptothecin treatment for 24 h resulted in RAD51 foci formation in Brca2LP/LP and Brca2LP/KO MEFs, indicating that BRCA2-DSS1 interaction is dispensable for RAD51 loading when homologous DNA is close during DNA replication. | Nat Commun. 2022 Apr 1;13(1):1751. |
| A431 cells | 10 μM | 6 h | Induced apoptosis and enhanced ectodomain shedding of Dsg2, resulting in accumulation of the 95 kDa fragment. | Oncogene. 2012 Mar 29;31(13):1636-48. |
| A549 cells | 5 µM | 24 h | To evaluate the apoptosis induced by Camptothecin, the results showed that Camptothecin significantly induced apoptosis but did not lead to the degradation of the telomeric G-overhang. | Nucleic Acids Res. 2005 Apr 14;33(7):2192-203. |
| HT1080 cells | 2.5-50 nM | 24 h | To evaluate the potentiation of cytotoxicity of DNA damaging agents by CRT0044876. Results showed that CRT0044876 did not potentiate the cytotoxicity of Camptothecin. | Nucleic Acids Res. 2005 Aug 19;33(15):4711-24. |
| Jurkat cells | 2 μM and 20 μM | 0, 1, 2, 3, 4, 5 h | Comparing the efficacy of ApoqPCR with other apoptosis quantifiers, the results showed that ApoqPCR was more sensitive in detecting and distinguishing low levels of apoptosis, and could more clearly resolve values at higher levels of apoptosis. | Nucleic Acids Res. 2012 Aug;40(15):e113. |
| PBMC | 0 to 0.2 μM, in 0.02 μM increments | 3.5 h | Evaluating the sensitivity of ApoqPCR in low-level apoptosis changes, the results showed that ApoqPCR has an advantage in detecting low-level apoptosis changes. | Nucleic Acids Res. 2012 Aug;40(15):e113. |
| Administration | Dosage | Frequency | Description | References | ||
| BALB/c mice | 4T1.2 breast cancer model | Intravenous injection | 5 mg/kg | Evaluate the distribution and antitumor efficacy of PEG 5K-Fmoc-VE 2/CPT-S-S-VE in tumor tissues | Biomaterials. 2015 Sep;62:176-87 | |
| CD-1 mice | Oral administration model | Oral | 5 mg/kg | Single dose, lasting 8 hours | To evaluate the enhancement effect of PAMAM dendrimers on the oral absorption of Camptothecin, results showed that both PAMAM G4.0 and G3.5 increased the oral absorption of Camptothecin, enhancing its concentration in blood and liver. | Int J Pharm. 2013 Nov 1;456(1):175-85 |
| Dose | Rat: 30 mg/kg[3] (i.g.) | ||||||||||||||||||
| Administration | i.g. | ||||||||||||||||||
| Pharmacokinetics |
|
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
2.87mL 0.57mL 0.29mL |
14.35mL 2.87mL 1.44mL |
28.71mL 5.74mL 2.87mL |
|
| CAS号 | 7689-03-4 |
| 分子式 | C20H16N2O4 |
| 分子量 | 348.35 |
| SMILES Code | [C@@]5(C2=C(C(N1CC4=C(C1=C2)N=C3C=CC=CC3=C4)=O)COC5=O)(CC)O |
| MDL No. | MFCD00081076 |
| 别名 | Campathecin; CPT; (+)-Camptothecin; 20(S)-Camptothecine; d-Camptothecin; Camptothecine; NSC 94600; MAG-CPT; (S)-(+)-Camptothecin |
| 运输 | 蓝冰 |
| InChI Key | VSJKWCGYPAHWDS-FQEVSTJZSA-N |
| Pubchem ID | 24360 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Keep in dark place,Inert atmosphere,2-8°C |
| 溶解方案 |
DMSO: 5 mg/mL(14.35 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 1M NaOH: 10 mg/mL(28.71 mM),配合低频超声,并调节pH至11 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1